December 2, 2025 09:00 AM EST Updated December 4, 04:25 AM PharmaIn Focus As ap­proval date looms, Cy­to­ki­net­ics gears up for David-and-Go­liath bat­tle with Bris­tol My­ers Elizabeth Cairns Senior biopharma journalist It has tak­en near­ly 30 years, but Cy­to­ki­net­ics is on the cusp of its first-ever ap­proval. Wall Street re­gards afi­camten — a once-dai­ly pill for a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER